Concomitant use of cholinesterase inhibitors and anticholinergics: Prevalence and outcomes

Journal of the American Geriatrics Society

Volumn 59, Issue 11, 2011, Pages 2069-2076

  Boudreau, Denise M ^a,b   Yu, Onchee ^a   Gray, Shelly L ^b   Raebel, Marsha A ^c,d   Johnson, Jeanene ^a   Larson, Eric B ^a,e  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c KAISER PERMANENTE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; anticholinergics; cholinesterase inhibitors; dementia; medication use

Indexed keywords

ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RANITIDINE; RIVASTIGMINE; SPASMOLYTIC AGENT; TACRINE;

ADULT; AGED; ARTICLE; AWARENESS; BLADDER SPASM; COHORT ANALYSIS; COMORBIDITY; DRUG USE; FEMALE; GASTROINTESTINAL TOXICITY; HEALTH CARE QUALITY; HUMAN; INTESTINAL SPASM; MAJOR CLINICAL STUDY; MALE; NURSING HOME; OUTCOME ASSESSMENT; PREVALENCE; RETROSPECTIVE STUDY; RISK; URINE INCONTINENCE;

AGED; CAUSE OF DEATH; CHOLINERGIC ANTAGONISTS; CHOLINESTERASE INHIBITORS; COLORADO; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NURSING HOMES; POPULATION SURVEILLANCE; PREVALENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 81755166228     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03654.x     Document Type: Article

References (42)

1. Qizilbash N, Whitehead A, Higgins J, et al. Cholinesterase inhibition for Alzheimer disease: A meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. JAMA 1998; 280: 1777-1782.
2. Shanks M, Kivipelto M, Bullock R, et al. Cholinesterase inhibition: Is there evidence for disease-modifying effects? Curr Med Res Opin 2009; 25: 2439-2446.
3. Alzheimer's Association. Alzheimer's Association Home Page [on-line]. Available at. Accessed September 28, 2010.
4. Winblad B,. Donepezil in severe Alzheimer's disease. Am J Alzheimers Dis Other Demen 2009; 24: 185-192.
5. Pepeu G, Giovannini MG,. Cholinesterase inhibitors and beyond. Curr Alzheimer Res 2009; 6: 86-96.
6. Birks J,. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; Jan 25;(1): CD005593.
7. Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. Clin Interv Aging 2008; 3: 211-225.
8. Kavirajan H, Schneider LS,. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6: 782-792.
9. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-397.
10. Hansen RA, Gartlehner G, Lohr KN, et al. Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis. Drugs Aging 2007; 24: 155-167.
11. Cancelli I, Beltrame M, Gigli GL, et al. Drugs with anticholinergic properties: Cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci 2009; 30: 87-92.
12. Carnahan RM, Lund BC, Perry PJ, et al. The concurrent use of anticholinergics and cholinesterase inhibitors: Rare event or common practice? J Am Geriatr Soc 2004; 52: 2082-2087.
13. Roe CM, Anderson MJ, Spivack B,. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 2002; 50: 836-842.
14. Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study. BMJ 2006; 332: 455-459.
15. Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: A clinical review. Clin Interv Aging 2009; 4: 225-233.
16. Han L, McCusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001; 161: 1099-1105.
17. Hilmer SN, Mager DE, Simonsick EM, et al. Drug burden index score and functional decline in older people. Am J Med 2009; 122: 1142-1149, e1141-1142.
18. Han L, Agostini JV, Allore HG,. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008; 56: 2203-2210.
19. Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-city study. Arch Intern Med 2009; 169: 1317-1324.
20. Cancelli I, Gigli GL, Piani A, et al. Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: A population-based study. J Clin Psychopharmacol 2008; 28: 654-659.
21. McLeod PJ, Huang AR, Tamblyn RM, et al. Defining inappropriate practices in prescribing for elderly people: A national consensus panel. CMAJ 1997; 156: 385-391.
22. Mintzer J, Burns A,. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000; 93: 457-462.
23. Fick DM, Cooper JW, Wade WE, et al. Updating the beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med 2003; 163: 2716-2724.
24. California Working Group on Guidelines for Alzheimer's Disease Management. Guideline for Alzheimer's Disease Management. Sacramanto: State of California Department of Public Health, 2008 Available at. Accessed September 6, 2011.
25. Lu CJ, Tune LE,. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry 2003; 11: 458-461.
26. Sink KM, Thomas J, 3rd, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: Long-term functional and cognitive outcomes. J Am Geriatr Soc 2008; 56: 847-853.
27. Carnahan RM, Lund BC, Perry PJ, et al. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity. J Clin Pharmacol 2006; 46: 1481-1486.
28. Carnahan RM, Lund BC, Perry PJ, et al. A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practice. Psychopharmacol Bull 2002; 36: 24-39.
29. Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008; 56: 1333-1341.
30. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383.
31. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
32. Wimo A, Winblad B, Aguero-Torres H, et al. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003; 17: 63-67.
33. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119-1122.
34. Woloshin S, Schwartz LM, Tremmel J, et al. Direct-to-consumer advertisements for prescription drugs: What are Americans being sold? Lancet 2001; 358: 1141-1146.
35. drugstore.com. drugstore.com Home Page [on-line]. Available at Accessed April 8, 2011.
36. Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005; 165: 808-813.
37. Lockhart IA, Mitchell SA, Kelly S,. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: Systematic review of the "real-world" evidence. Dement Geriatr Cogn Disord 2009; 28: 389-403.
38. Johnell K, Fastbom J,. Concurrent use of anticholinergic drugs and cholinesterase inhibitors: Register-based study of over 700,000 elderly patients. Drugs Aging 2008; 25: 871-877.
39. Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 2007; 55: 1517-1523.
40. Modi A, Weiner M, Craig BA, et al. Concomitant use of anticholinergics with acetylcholinesterase inhibitors in Medicaid recipients with dementia and residing in nursing homes. J Am Geriatr Soc 2009; 57: 1238-1244.
41. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004; 104: 1042-1050.
42. Boudreau DM, Doescher MP, Jackson JE, et al. Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 2004; 38: 1317-1318.